With Vertex Pharmaceuticals' latest quarterly earnings scheduled for Sunday, May 3rd, analysts estimate an earnings per share of $4.29.
Vertex Pharmaceuticals' current price stands at $430.31, marking a $4.3 increase from the previous close. The trading volume is $253,486, reflecting an 18.42% increase relative to the average.
The company's most recent earnings, reported on Wednesday, February 11th, showed an earnings per share of $5.03, slightly below the consensus estimate of $5.11.
Vertex Pharmaceuticals reported a free cash flow of $348.6 million and a net change in cash of $140 million. The company's operating cash flow reached $498 million, with capital expenditures at $-149.4 million.
Revenue for the period totaled $3.23 billion, with a gross profit of $2.76 billion. The net income stood at $1.19 billion, resulting in an earnings per share of $4.69.
Key ratios include a net profit margin of 36.91%, a return on equity of 6.38%, and a price-to-earnings ratio of 24.16.
Vertex Pharmaceuticals' total assets amount to $26.14 billion, with total liabilities at $7.48 billion. The company holds $5 billion in cash and cash equivalents.
This real-time financial report provides insights into Vertex Pharmaceuticals' recent performance and financial health, shedding light on key metrics and upcoming events.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.